MAQS advised Oblique Therapeutics on the deal.Oblique Therapeutics AB (publ) completed a rights issue of approximately SEK 53.2 million. Oblique Therapeutics is a privately held Swedish…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
